Author:
David Pierre-Marie,Lata Kayley Laura,Bouthillier Marie-Eve,Bélisle-Pipon Jean-Christophe
Abstract
AbstractDrug exceptional access programs (DEAPs) exist across Canada to address gaps in access to pharmaceuticals. These programs circumvent standard procedures, raising epistemic, economic, social and political issues. This commentary provides insights into these issues by revealing the context and procedures on which these programs depend.
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Rayson D, Gandhi S, Joy AA, Brezden-Masley C, Gelmon KA, Sehdev S, et al. Access to Neoadjuvant Pertuzumab for HER2 positive breast Cancer in Canada: a Dilemma increasingly difficult to explain. Curr Oncol. 2022;29(12):9891–5.
2. Grundy Q, Quanbury A, Hart D, Chaudhry S, Tavangar F, Lexchin J, et al. Prevalence and nature of manufacturer-sponsored patient support programs for prescription drugs in Canada: a cross-sectional study. CMAJ. 2023;195(46):E1565–76.
3. Cambourieu C. Les médicaments d’ordonnance - État de la situation au Québec / recherche et rédaction [.] [Internet]. Commissaire à la santé et au bien-être Québec; 2014 [cited 2022 Nov 7]. Available from: http://numerique.banq.qc.ca/.
4. Ministère de la santé et des services sociaux du Québec. La Politique Du médicament. Gouvernement du Québec; 2007.
5. Médicaments d’exception | RAMQ [Internet]. [cited 2022 Nov 2]. Available from: https://www.ramq.gouv.qc.ca/fr/professionnels/pharmaciens/medicaments/medicaments-patient-exception/Pages/medicaments-exception.aspx.